Which condition does not have a listed indication for Ezetimibe?

Ezetimibe is primarily used to lower cholesterol levels. Its indications include treatment for primary hypercholesterolemia, mixed hyperlipidemia, and heterozygous familial hypercholesterolemia. The key distinction regarding familial hypercholesterolemia is that it exists in two forms: heterozygous and homozygous.

In the context of this question, the indication for ezetimibe does not extend to homozygous familial hypercholesterolemia, which is a more severe form of the condition, often requiring more aggressive treatments and typically involving combination therapy with statins or PCSK9 inhibitors. Ezetimibe can be considered in cases of heterozygous familial hypercholesterolemia, but it has not been specifically indicated for the homozygous form due to the complexity and severity associated with it.

Thus, the condition that does not have a listed indication for ezetimibe is likely the homozygous type of familial hypercholesterolemia, recognizing that it is designed to be a part of a more complex treatment regimen rather than a standalone therapy.